PolyPid Ltd
polypid.comWhat Do They Do?
Develops long-acting medicines that release drugs at treatment sites, including a candidate to prevent surgical infections and programs for metabolic diseases and cancer.
20-F for FY2025, filed Feb 25, 2026We are an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where…View ↗
In addition to our lead program D-PLEX100, our pipeline includes early-stage programs. In July 2025, we unveiled our long-acting GLP-1…View ↗
OncoPLEX, PolyPid’s lead intra-tumoral cancer therapy drug candidate, can potentially provide controlled local exposure to docetaxel, one…View ↗
How Do They Make Money?
No revenue reported yet.
20-F for FY2025, filed Feb 25, 2026
Who Are Their Customers?
Advanz holds exclusive rights to market and distribute D-PLEX100 in the EEA and United Kingdom. PolyPid plans to launch D-PLEX100 worldwide through commercial partnerships if it is approved.
20-F for FY2025, filed Feb 25, 2026
How Are They Changing?
Expanded into metabolic diseases
The earlier report focused on surgical infections and cancer. The latest report adds a long-acting delivery platform aimed at metabolic diseases and groups its expanded delivery technologies under Kynatrix.
20-F for FY2022, filed Mar 31, 2023 20-F for FY2025, filed Feb 25, 2026
Who Do They Compete With?
Competes with BoneSupport
20-F for FY2025, filed Feb 25, 2026The current SoC for preventing SSIs involves the implementation of a range of treatment and prevention measures before, during and after…View ↗
Loading...
